Fampridine
Nerve Injury
John ElfarSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Nerve Injury cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Uppsala University | Phase 2 | B |
Ethosuximide University Hospital, Clermont-Ferrand | Phase 2 | B |
VENLOR Uppsala University | Phase 2 | B |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE University Health Network, Toronto | Early Phase 1 | CC |
Neuron012703 Targeted Medical Pharma | Phase 2 | NR |
Same molecule, other indications
Fampridine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →